The Gen 1.0 biologics that provide immediacy and the Gen 1.5 biologics that provide immediacy and incremental durability are meaningful for patients and physicians Good efficacy, limited durability Good immediacy, incremental durability Q4W Q8W Q12W Q16W Wet AMD DME DR RVO Wet AMD DME DR RVO Wet AMD DME RVO Wet AMD DME DR Dosing regimen per label for approved intravitreal biologics and estimated worldwide sales in 2025 Q20W Q24W ~718M in 2025 1,2 ~$5.3B in 2025 3,4 ~$5.3B in 2025 2 ~$2.6B in 2025 4 The commercial success of new branded therapies is a testament to: • The power of the intravitreal biologic as the mainstay of therapy • The unmet need that remains for patients 1. Novartis 2025 FY Financial Results. 2. Roche Finance Report 2025. 3. Bayer FY 2025 Investor Call, Pharma sales by product split. March 04, 2026. 4. Regeneron Corporate Presentation, January 2026. RVO Q4W dosing flexibility Gen 1.5 Gen 1.0 17